Bailard, Inc. Regeneron Pharmaceuticals, Inc. Transaction History

Bailard, Inc.

$3.58 Billion
Q1 2024

A detailed history of Bailard, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 12,144 shares of REGN stock, worth $12.4 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

12,144

Previous 12,103 0.34%

Holding current value

$12.4 Million

Previous $10.6 Million 9.96%

% of portfolio

0.33%

Previous 0.32%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$902.69 - $993.35 $37,010 - $40,727	41 Added 0.34%	12,144 $11.7 Million
Q4 2023 Feb 02, 2024	SELL	$775.18 - $881.7 $24,030 - $27,332	-31 Reduced 0.26%	12,103 $10.6 Million
Q3 2023 Oct 24, 2023	BUY	$692.45 - $844.37 $203,580 - $248,244	294 Added 2.48%	12,134 $9.99 Million
Q2 2023 Jul 20, 2023	BUY	$700.03 - $830.35 $1.74 Million - $2.06 Million	2,486 Added 26.58%	11,840 $8.51 Million
Q1 2023 May 08, 2023	BUY	$680.49 - $826.97 $193,259 - $234,859	284 Added 3.13%	9,354 $7.69 Million

Q4 2022 Feb 02, 2023	BUY	$705.89 - $766.39 $146,119 - $158,642	207 Added 2.34%	9,070 $6.54 Million
Q3 2022 Oct 18, 2022	BUY	$573.97 - $724.32 $1.57 Million - $1.98 Million	2,732 Added 44.56%	8,863 $6.11 Million
Q2 2022 Jul 27, 2022	BUY	$548.35 - $738.84 $3.2 Million - $4.31 Million	5,831 Added 1943.67%	6,131 $3.62 Million
Q1 2022 Apr 25, 2022	SELL	$595.12 - $698.43 $416,584 - $488,900	-700 Reduced 70.0%	300 $210,000
Q4 2015 Jan 29, 2018	BUY	N/A	1,000	1,000 $0

Others Institutions Holding REGN

# of Institutions

1,427

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $110B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account